Literature DB >> 16820142

Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses.

Jeff S Isenberg1, David A Wink, David D Roberts.   

Abstract

OBJECTIVE: Endothelial-derived nitric oxide (NO), by increasing cGMP, is a major physiological regulator of vascular tone and of vascular smooth muscle cell (VSMC) adhesion, chemotaxis, and proliferation. Thrombospondin-1 is a potent antagonist of NO/cGMP signaling in endothelial cells. Because endothelial and VSMC typically exhibit opposing responses to thrombospondin-1, we examined thrombospondin-1 effects on NO signaling in VSMC.
METHODS: Effects of exogenous thrombospondin-1 on human VSMC adhesion, chemotaxis, proliferation, and cGMP signaling were examined. Endogenous thrombospondin-1 function was characterized by comparing NO signaling in VSMC from wild type and thrombospondin-1 null mice.
RESULTS: Picomolar concentrations of exogenous thrombospondin-1 prevented adhesive, chemotactic, and proliferative responses of human aortic VSMC stimulated by low dose NO. A recombinant CD36-binding domain of thrombospondin-1 or antibody ligation of CD36 similarly inhibited NO-stimulated VSMC responses. Thrombospondin-1 and CD36 ligation inhibited NO responses in VSMC by preventing cGMP accumulation. Thrombospondin-1 null VSMC responses to NO and cGMP signaling were enhanced relative to wild type murine VSMC.
CONCLUSIONS: In the presence of NO, thrombospondin-1 is converted from a weak stimulator to a potent inhibitor of VSMC responses. Both exogenous and endogenous thrombospondin-1 inhibit NO signaling in VSMC. This activity is mediated by the type 1 repeats and utilizes the same CD36-dependent cGMP signaling pathway in endothelial and VSMC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820142     DOI: 10.1016/j.cardiores.2006.05.024

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  61 in total

Review 1.  The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress via CD47.

Authors:  David D Roberts; Thomas W Miller; Natasha M Rogers; Mingyi Yao; Jeffrey S Isenberg
Journal:  Matrix Biol       Date:  2012-01-14       Impact factor: 11.583

2.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

Review 3.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

4.  Thrombospondin-1 inhibition of vascular smooth muscle cell responses occurs via modulation of both cAMP and cGMP.

Authors:  Mingyi Yao; David D Roberts; Jeff S Isenberg
Journal:  Pharmacol Res       Date:  2010-10-29       Impact factor: 7.658

Review 5.  CD47: a new target in cardiovascular therapy.

Authors:  Jeff S Isenberg; David D Roberts; William A Frazier
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-01-10       Impact factor: 8.311

Review 6.  Molecular regulation of tumor angiogenesis and perfusion via redox signaling.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Chem Rev       Date:  2009-07       Impact factor: 60.622

Review 7.  Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease.

Authors:  Natasha M Rogers; Kedar Ghimire; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

8.  Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration.

Authors:  Saumya Ramanathan; Stacy Mazzalupo; Scott Boitano; William R Montfort
Journal:  Biochemistry       Date:  2011-08-16       Impact factor: 3.162

9.  Stainless steel ions stimulate increased thrombospondin-1-dependent TGF-beta activation by vascular smooth muscle cells: implications for in-stent restenosis.

Authors:  Manuel A Pallero; Melissa Talbert Roden; Yiu-Fai Chen; Peter G Anderson; Jack Lemons; Brigitta C Brott; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2009-12-16       Impact factor: 1.934

10.  Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts.

Authors:  Jeff S Isenberg; Loretta K Pappan; Martin J Romeo; Mones Abu-Asab; Maria Tsokos; David A Wink; William A Frazier; David D Roberts
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.